Retrospective 17 COVID+ patients treated with favipiravir and 17 matched controls in Japan, showing faster viral clearance with treatment. Favipiravir 3600mg day one, 1600mg per day for up to 14 days.
hospitalization time, 7.5% lower, HR 0.93, p = 0.84, treatment 17, control 17.
|
viral clearance time, 55.2% lower, HR 0.45, p = 0.04, treatment 17, control 17.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Shinada et al., 3/24/2022, retrospective, Japan, Asia, peer-reviewed, 11 authors, study period 28 May, 2020 - 26 September, 2020, average treatment delay 8.9 days.
Contact:
takashisato1220@gmail.com (corresponding author), kanakoshinada7@gmail.com, mshinopy@gmail.com, shin.ohta0915@gmail.com, miwapicco@outlook.jp, shinkai050169@gmail.com, m-mine@marianna-u.ac.jp, sayamrym@niid.go.jp, yuadachi@niid.go.jp, matt@niid.go.jp, ytakahas@niid.go.jp.